Skip to main content
TipRanks
Go Ultimate75% OFF

Alpa Laboratories Limited (ALPA) AI Stock Analysis

3 Followers
IN:ALPA

Alpa Laboratories Limited

(NSE:ALPA)

Select Model
Rating:57Neutral
Price Target:INR 53.00â–²(2.71% Upside)
Action:reiterated
Date:09/06/26

Solid financial performance led by balance sheet strength is the primary positive driver, offset by bearish technical signals and elevated valuation multiples.

Positive Factors
Conservative Balance SheetVery low leverage gives Alpa financial resilience and reduces the burden of interest and refinancing obligations. Steadily expanding equity also indicates retained capital accumulation, supporting asset growth and preserving flexibility to fund operations or strategic investments.
Negative Factors
Recent Revenue ContractionThe latest revenue decline, following uneven growth in prior years, points to inconsistent commercial momentum. Sustained top-line weakness could limit operating leverage, reduce the scale benefits available to manufacturing activities, and make future earnings growth less predictable.

Alpa Laboratories Limited (ALPA) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:ALPA-35.09%INDA-5.15%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.11B
Dividend Yield
―
Average Volume (3M)
4,265
Price to Earnings (P/E)
30.9
Beta (1Y)
1.29
Revenue Growth
0.46%
EPS Growth
-83.31%
Country
India
Employees
457
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Alpa Laboratories Limited Business Overview & Revenue Model

Company Description

Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-gra...

Alpa Laboratories Limited Financial Statement Overview

Summary

Strong balance sheet with growing equity to 1.86B and minimal debt supports stability (sub-score 85), while income growth to 150M net income and cash flow improvements are offset by margin erosion and volatility (sub-scores 65 and 55).

Income Statement

65Positive

Balance Sheet

85Very Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.16B1.06B1.12B1.09B924.10M1.11B
Gross Profit243.95M136.09M193.99M188.90M307.44M344.08M
EBITDA75.79M190.47M281.01M229.96M174.43M214.31M
Net Income43.78M150.10M195.03M167.76M125.83M140.92M
Balance Sheet
Total Assets02.42B2.23B1.82B1.67B1.55B
Cash, Cash Equivalents and Short-Term Investments1.38B1.38B1.13B928.54M808.42M702.74M
Total Debt025.08M343.00K52.47M23.04M58.47M
Total Liabilities-1.86B558.64M511.59M304.62M326.92M335.08M
Stockholders Equity1.86B1.86B1.71B1.52B1.35B1.22B
Cash Flow
Free Cash Flow89.97M84.84M-21.42M-27.36M77.78M77.49M
Operating Cash Flow106.65M124.37M92.37M36.49M89.04M99.40M
Investing Cash Flow-144.58M-143.01M-35.13M-133.36M21.27M-156.10M
Financing Cash Flow22.40M24.80M-52.47M25.83M-37.93M54.42M

Alpa Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price51.60

Price Trends

50DMA56.92Negative
100DMA61.75Negative
200DMA64.17Negative

Market Momentum

MACD-0.73Negative
RSI43.61Neutral
STOCH37.89Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Negative. The current price of 51.60 is below the 20-day moving average (MA) of 52.60, below the 50-day MA of 56.92, and below the 200-day MA of 64.17, indicating a bearish trend. The MACD of -0.73 indicates Negative momentum. The RSI at 43.61 is Neutral, neither overbought nor oversold. The STOCH value of 37.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALPA.

Alpa Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ALPA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.41B10.87――9.40%34.12%
IN:BROOKSIN:BROOKS61NeutralINR 2.00B2.74――-14.88%431.30%
IN:ALPAIN:ALPA57NeutralINR 1.09B30.92――0.46%-83.31%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:BALPHARMAIN:BALPHARMA53NeutralINR 1.40B17.45―1.36%18.79%-2.58%
IN:BIOFILCHEMIN:BIOFILCHEM47NeutralINR 518.16M105.55――9.31%-82.71%
IN:NECLIFEIN:NECLIFE43NeutralINR 1.99B-3.02――-99.85%78.93%

* General Sector Average

Performance Comparison

-50%0%50%IN:ALPAIN:BALPHARMAIN:BIOFILCHEMIN:BROOKSIN:NECLIFEIN:PARDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ALPA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ALPAAlpa Laboratories Limited51.60-28.30-35.42%
IN:BALPHARMABal Pharma Limited87.9511.3714.85%
IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd.31.84-7.12-18.28%
IN:BROOKSBrooks Laboratories Limited67.90-37.55-35.61%
IN:NECLIFENectar Lifesciences Ltd.10.23-3.91-27.65%
IN:PARPar Drugs and Chemicals Limited114.8022.1523.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026